124 related articles for article (PubMed ID: 15086431)
1. Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma.
de Vries MJ; Veerman AJ; Zwaan CM
Br J Haematol; 2004 May; 125(3):414-5. PubMed ID: 15086431
[No Abstract] [Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
4. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma.
Okur FV; Oguz A; Karadeniz C; Citak C; Poyraz A; Boyunaga O
Pediatr Hematol Oncol; 2006; 23(1):25-31. PubMed ID: 16326409
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in a child with relapsed Burkitt lymphoma.
Bay A; Dogan M; Acikgoz M; Oner AF
Pediatr Blood Cancer; 2007 Aug; 49(2):218. PubMed ID: 16847929
[No Abstract] [Full Text] [Related]
6. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
7. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
Seifert G; Reindl T; Lobitz S; Seeger K; Henze G
Haematologica; 2006 Jun; 91(6 Suppl):ECR23. PubMed ID: 16785126
[TBL] [Abstract][Full Text] [Related]
8. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
Rothe A; Schulz H; Elter T; Engert A; Reiser M
Haematologica; 2004 Jul; 89(7):875-6. PubMed ID: 15257947
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
Jaime-Pérez JC; Rodríguez-Romo LN; González-Llano O; Chapa-Rodríguez A; Gómez-Almaguer D
Br J Haematol; 2009 Mar; 144(5):794-5. PubMed ID: 19036096
[No Abstract] [Full Text] [Related]
10. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
Claviez A; Eckert C; Seeger K; Schrauder A; Schrappe M; Henze G; von Stackelberg A
Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
12. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab.
Turzanski J; Daniels I; Haynes AP
Br J Haematol; 2009 Apr; 145(1):137-40. PubMed ID: 19183195
[No Abstract] [Full Text] [Related]
13. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
Attias D; Weitzman S
Curr Opin Pediatr; 2008 Feb; 20(1):17-22. PubMed ID: 18197034
[TBL] [Abstract][Full Text] [Related]
14. Remission induction with single agent Rituximab in a child with multiply relapsed precursor-B ALL.
Morris ES; Vora A
Br J Haematol; 2007 Oct; 139(2):344-5. PubMed ID: 17897313
[No Abstract] [Full Text] [Related]
15. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Łuczyński W; Krawczuk-Rybak M
Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
[TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E
J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
